Ixchelsis Ltd is a clinical-stage biotechnology company developing an oxytocin receptor antagonist (IX-01) for the treatment of premature ejaculation (PE). IX-01 is a clinical stage asset that has the potential to be the best in class pharmacological approach for the treatment of PE.
To date IX-01 has completed in Phase 1, single and multiple ascending dose studies in healthy male volunteers as well as relative bioavailability studies on solid dosage formulations. Ixchelsis achieved positive proof of concept for IX-01 in 2016, in a study of patients with severe lifelong PE. IX-01 is currently being progressed through a Phase II B dose ranging study. Ixchelsis is funded by TVM Life Science Ventures VII and Pfizer Ventures. Ixchelsis is led by a Management team with extensive experience in
pharmaceutical R&D, particularly in the male sexual health therapeutic area.